Compare CUE & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | EML |
|---|---|---|
| Founded | 2014 | 1858 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 145.5M |
| IPO Year | 2017 | 1995 |
| Metric | CUE | EML |
|---|---|---|
| Price | $30.34 | $24.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | ★ 137.0K | 20.3K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | 61.11 | ★ 185.40 |
| EPS | N/A | ★ 0.11 |
| Revenue | $27,466,000.00 | ★ $248,970,345.00 |
| Revenue This Year | N/A | $19.05 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $219.36 |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $17.61 |
| 52 Week High | $45.50 | $29.91 |
| Indicator | CUE | EML |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 46.30 |
| Support Level | $24.49 | $18.34 |
| Resistance Level | $32.82 | $27.19 |
| Average True Range (ATR) | 4.17 | 0.97 |
| MACD | -0.22 | -0.37 |
| Stochastic Oscillator | 31.96 | 26.30 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.